We spatially mapped the expression of possible immunotherapeutic targets like EpCAM, uniformly expressed in all samples, and HER2, demonstrating a higher degree of intratumoral heterogeneity, particularly in the CRC sample. This evidence concerns the gene ERBB2 and colorectal carcinoma.